# X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
Canonical URL: https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-participate-in-guggenheim-s-emerging-outlook-biotech-summi-7fce9300
Ticker: XFOR
Company: X4 Pharmaceuticals
Source: X4 Pharmaceuticals
Published: 2026-02-03 12:00 EST
## Summary

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology...

## Article Body
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York.

The X4 team will hold a fireside chat on February 12th at 12:30 p.m. ET and will be available for one-on-one meetings with investors.

A webcast of the fireside chat will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.x4pharma.com .

About X4 Pharmaceuticals X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in patients with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact: IR@X4pharma.com
## Recent Company News
- 2026-07-07 20:30 EST — [X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--477fc08a) — Source: X4 Pharmaceuticals
- 2026-07-01 11:00 EST — [X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-appoints-kelly-gold-experienced-chief-financial-officer-to-it-316d9f27) — Source: X4 Pharmaceuticals
- 2026-06-01 20:30 EST — [X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f8e34e98) — Source: X4 Pharmaceuticals
- 2026-05-27 11:00 EST — [X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-conference-7aa62ad2) — Source: X4 Pharmaceuticals
- 2026-05-06 11:15 EST — [X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-cor-86158817) — Source: X4 Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)